Scholarlink

Aim/introduction <p>The effects of weekly semaglutide on glucose profiles and body weight in people with obesity and type 2 diabetes (T2D) undergoing maintenance hemodialysis (HD) remain poorly understood.</p> Material and methods <p>This single-arm, observational study evaluated the effects and safety of weekly semaglutide in 11 people with obesity and T2D on HD (seven men, 57 ± 10&#xa0;years). Continuous glucose monitoring (CGM) was used to assess changes in glycemic profiles, and changes in dry weight were also analyzed.</p> Results <p>After 6 months of treatment, hemoglobin A1c (HbA1c) and glycated albumin significantly decreased from 7.8 ± 1.2% and 23.6 ± 5.2% to 6.9 ± 1.1% and 19.6 ± 4.3%, respectively (<i>P</i> = 0.0318, <i>P</i> = 0.0062). CGM data showed that mean sensor glucose levels decreased from 172.0 ± 36.2&#xa0;mg/dL to 138.1 ± 25.4&#xa0;mg/dL (<i>P</i> = 0.0177), and glucose variability (standard deviation) decreased from 56.8 ± 24.4&#xa0;mg/dL to 42.1 ± 12.8&#xa0;mg/dL (<i>P</i> = 0.0264). Time in range (70–180&#xa0;mg/dL) significantly increased from 57.0% (34.0–86.0%) to 78.0% (51.4–97.0%) (<i>P</i> = 0.0420). Additionally, semaglutide significantly reduced dry weight from 86.2 ± 12.7&#xa0;kg to 83.2 ± 13.1&#xa0;kg (<i>P</i> = 0.0285). No serious adverse events were observed.</p> Conclusions <p>These findings suggest that weekly semaglutide is a safe and effective option for improving glycemic control and weight management in people with obesity and T2D on HD.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Semaglutide in people with obesity and type 2 diabetes on hemodialysis: a prospective analysis of glycemic and weight outcomes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月29日

查看全文
  • Akinori Hayashi,
  • Ibuki Moriguchi,
  • Naoyuki Kobayashi

摘要

Aim/introduction

The effects of weekly semaglutide on glucose profiles and body weight in people with obesity and type 2 diabetes (T2D) undergoing maintenance hemodialysis (HD) remain poorly understood.

Material and methods

This single-arm, observational study evaluated the effects and safety of weekly semaglutide in 11 people with obesity and T2D on HD (seven men, 57 ± 10 years). Continuous glucose monitoring (CGM) was used to assess changes in glycemic profiles, and changes in dry weight were also analyzed.

Results

After 6 months of treatment, hemoglobin A1c (HbA1c) and glycated albumin significantly decreased from 7.8 ± 1.2% and 23.6 ± 5.2% to 6.9 ± 1.1% and 19.6 ± 4.3%, respectively (P = 0.0318, P = 0.0062). CGM data showed that mean sensor glucose levels decreased from 172.0 ± 36.2 mg/dL to 138.1 ± 25.4 mg/dL (P = 0.0177), and glucose variability (standard deviation) decreased from 56.8 ± 24.4 mg/dL to 42.1 ± 12.8 mg/dL (P = 0.0264). Time in range (70–180 mg/dL) significantly increased from 57.0% (34.0–86.0%) to 78.0% (51.4–97.0%) (P = 0.0420). Additionally, semaglutide significantly reduced dry weight from 86.2 ± 12.7 kg to 83.2 ± 13.1 kg (P = 0.0285). No serious adverse events were observed.

Conclusions

These findings suggest that weekly semaglutide is a safe and effective option for improving glycemic control and weight management in people with obesity and T2D on HD.